GlaxoSmithKline (GSK) published the results of its Survey of Antibiotic Resistance (SOAR) in Russia. The collected data revealed high sensitivity of the main bacteria causing respiratory infections to amoxicillin/clavulanate and fluoroquinolones.
Data collected in the Russian Federation showed that the sensitivity of Streptococcus pneumoniae and Haemophilus influenzae to amoxicillin/clavulanate was 95% and 97.5%, respectively (100% under EUCAST and CLSI criteria). Russia also continues to demonstrate high sensitivity of both pathogens to fluoroquinolones (98.6% of Haemophilus influenzae isolates and up to 100% of S. Pneumoniae isolates are sensitive to anti-bacterial drugs of this class).
At the same time, the survey in Russia revealed a low level of sensitivity of S. Pneumoniae to macrolide antibiotics (clarithromycin, azithromycin) at the level of only 68.8%, while the sensitivity of Haemophilus influenzae to clarithromycin and azithromycin under EUCAST criteria did not exceed 0.4% and 2.2%, respectively.
Information obtained in the Russian Federation is consistent with the data on sensitivity of microorganisms observed in other countries and published earlier. SOAR enables practitioners to obtain contemporary data (2014-2016) on the state of antibiotic resistance in the treatment of community-acquired respiratory bacterial infections in Russia, as well as the information on worldwide trends in the formation of bacteria resistance to antibiotics.